-Highfrequency echocardiography and high-field-strength magnetic resonance imaging (MRI) are new noninvasive methods for quantifying pulmonary arterial hypertension (PAH) and right ventricular (RV) hypertrophy (RVH). We compared these noninvasive methods of assessing the pulmonary circulation to the gold standard, cardiac catheterization (micromanometer-tipped catheters), in rats with monocrotaline-induced PAH and normal controls. Closed-chest, SpragueDawley rats were anesthetized with inhaled isoflurane (25 monocrotaline, 6 age-matched controls). Noninvasive studies used 37.5-MHz ultrasound (Vevo 770; VisualSonics) or a 9.4-T MRI (Bruker BioSpin). Catheterization used a 1.4-F micromanometer-tipped Millar catheter and a thermodilution catheter to measure cardiac output (CO). We compared noninvasive measures of pulmonary artery (PA) pressure (PAP) using PA acceleration time (PAAT) and CO, using the geometric PA flow method and RV free wall (RVFW) thickness/mass with cardiac catheterization and/or autopsy. Blinded operators performed comparisons using each method within 2 days of another. In a subset of rats with monocrotaline PAH, weekly echocardiograms, catheterization, and autopsy data assessed disease progression. Heart rate was similar during all studies (Ͼ323 beats/min). PAAT shortened, and the PA flow envelope displayed systolic "notching," reflective of downstream vascular remodeling/stiffening, within 3 wk of monocrotaline. MRI and echocardiography measures of PAAT were highly correlated (r 2 ϭ 0.87) and were inversely proportional to invasive mean PAP (r 2 ϭ 0.72). Mean PAP by echocardiography was estimated as 58.7 Ϫ (1.21 ϫ PAAT). Invasive and noninvasive CO measurement correlated well (r 2 Ն 0.75). Noninvasive measures of RVFW thickness/mass correlated well with postmortem measurements. We conclude that high-resolution echocardiography and MRI accurately determine CO, PAP, and RV thickness/mass, offering similar results as high-fidelity right heart catheterization and autopsy, and that PAAT accurately estimates PAP and permits serial monitoring of experimental PAH. These tools are useful for assessment of the rodent pulmonary circulation and RVH. inhaled anesthesia; pulmonary artery acceleration time; pulmonary hemodynamics; right ventricular hypertrophy; rodent models of pulmonary hypertension WORLD HEALTH ORGANIZATION (WHO) category 1 pulmonary hypertension (PH), or pulmonary arterial hypertension (PAH), is a disease of the resistance pulmonary vasculature that leads to mortality due to right ventricular (RV) failure. Rodent models are increasingly used to identify mechanisms and therapies for PAH with the hope of translating research discoveries to humans. Rodent models of PAH require accurate assessment of pulmonary hemodynamics to ensure that the etiology of the PH is correctly categorized and to accurately track disease progression and regression without prematurely killing valuable research animals. The careful categorization used to distinguish PAH from other pulmonary hypertensive conditions is often overlooked in rodent models, and hemodynamic assessment of it is often superficial. Attribution of the cause of PH to the pulmonary vasculature, rather than occult left ventricular (LV) or valvular disease, is often done poorly in rodent studies. Rodent studies often lack measures of cardiac output (CO), LV end-diastolic pressure (LVEDP), or pulmonary vascular resistance (PVR) and seldom measure RV mass except at autopsy. Moreover, accurate means of monitoring disease state without killing the animal are needed since the models are often expensive to create [e.g., transgenic mice overexpressing the serotonin transporter (9) or a dominantnegative form of the bone morphogenetic protein receptor, BMPRII (39)] or develop PAH slowly [such as the fawnhooded rat (2)]. Noninvasive techniques could potentially save researchers money and more accurately categorize and quantify the PH in small animal models, which are increasingly important (35). Finally, since the translation from rodent experiments to human trials can be relatively rapid, accurate categorization of the efficacy of experimental therapies is crucial. For example, imatinib (7, 32) and sorafenib (8, 28) both went from animal PAH studies to human clinical trials in less than 2 years.
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In humans, a good correlation exists between pulmonary hemodynamics, as evaluated by echocardiography (Echo), magnetic resonance imaging (MRI), and catheterization (Cath) (3, 12, 22, 23, 27) . However, validation studies of noninvasive techniques in animal models are limited. Jones et al. (15) demonstrated a good correlation between M-mode and Doppler Echo vs. right heart Cath in the rat monocrotaline (MCT) PAH model. Schwenke et al. (33) used iodine contrast to image small pulmonary arteries (PA) in the closed-chest rat, using monochromatic synchrotron radiation, and showed that this microangiographic technique could detect the dynamic changes that occurred with hypoxic pulmonary vasoconstriction. Admittedly, technical challenges exist in noninvasively assessing rodents, including access to appropriate imaging equipment (operated by skilled imaging professionals) and selection of anesthetic agents, which do not alter heart rate or hemodynamics. Likewise, there are challenges in performing cardiac Cath in small animals, including mastering the use of high-fidelity catheters, measurement of CO, and obtaining vascular access without a thoracotomy or blood loss.
Recent miniaturization and refinement of imaging technology for rodents such as high-frequency Echo probes (Ͼ30 MHz) and high-field-strength MRI machines (9.4 T) have facilitated noninvasive characterization of the pulmonary circulation in rodents (1, 14, 30) . These newer noninvasive methods have not been simultaneously analyzed and validated against the micromanometer-tipped cardiac catheters, another advance in rodent physiological assessment. In this study, we sought to: 1) compare high-resolution Echo Doppler and highfield-strength MRI with each other and against the "gold standard," high-fidelity right heart Cath, for measurement of pulmonary hemodynamics in normal rats and rats with MCTinduced PAH; 2) validate Echo and MRI for quantifying RV thickness and mass against postmortem findings; and 3) describe imaging and anesthetic methodology that may be useful to investigators.
METHODS

Animal Protocol
The University of Chicago Institutional Animal Care and Use Committee approved all protocols. Six-week-old male Sprague-Dawley rats weighing 260 -280 g were purchased from Charles Rivers Laboratories (Wilmington, MA). We studied a total of 31 rats. PH was induced by a single, subcutaneous injection of MCT (60 mg/kg; Sigma, St. Louis, MO; n ϭ 25), as described previously (26) . Control rats were injected with saline subcutaneously (n ϭ 6). We used 3 methods to assess pulmonary hemodynamics in lightly anesthetized, closed-chest rats: high-frequency 2-dimensional (2-D), M-mode, and pulsed-wave Doppler Echo (Vevo 770 ultrasound system and a 37.5-MHz transducer; VisualSonics, Toronto, Ontario, Canada); highfield-strength, phase-contrast cine MRI (9.4-T Bruker BioSpec system; Bruker BioSpin, Ettlingen, Germany); and high-fidelity right heart Cath (1.4-F Millar micromanometer catheter; Millar Instruments, Houston, TX). Echo, MRI, and Cath were performed 4 wk after injection of MCT/saline. In addition, a subset of MCT rats had Echo and Cath at weeks 1 (n ϭ 3), 2 (n ϭ 3), 3 (n ϭ 6), and 4 (n ϭ 13). Data acquisition was performed by imaging/Cath scientists who were blinded to the results of the other modalities. Measurements by each technique were performed within 0 -2 days of each other. The average time intervals between techniques were: Echo vs. Cath, 0.7 Ϯ 0.3 days; MRI vs. Cath, 0.7 Ϯ 0.3 days; and MRI vs. Echo, 0.3 Ϯ 1.7 days. Supplemental Fig. S1 (available in the data supplement online at the AJP-Lung Cellular and Molecular Physiology web site) describes the study flow diagram.
Anesthesia and Monitoring
Experiments were perfumed with the rat in the supine position for Echo and Cath vs. a prone position for MRI. All 3 methods were conducted using inhaled isoflurane. Anesthesia was induced by placing the rat in an anesthesia induction chamber with gas flow at 2-3 l/min, and the isoflurane was delivered via vaporizer (Vetamac, Rossville, IN) at 3-4%. The exhaust was connected to the Omnicon F/Air device (AM Bickford). After induction, animals were maintained on the following isoflurane doses: 1.5-2% (Echo and MRI) or 3% isoflurane (Cath). The average dose (duration) of isoflurane was: Echo, 1.8 Ϯ 0.1% (ϳ24 min); MRI, 1.8 Ϯ 0% (ϳ60 min); and Cath, 3 Ϯ 0% (ϳ40 min). The anesthetic was mixed with 100% oxygen for MRI and Cath vs. medical air for Echo. After confirming adequate analgesia (absence of paw pinch reflex), animals were secured on the imaging platform with dermatological tape.
During Echo and MRI studies, rats breathed spontaneously and anesthesia was delivered using a facemask, whereas during the Cath, rats were intubated and ventilated in a volume-controlled mode (2.5-3.0 ml tidal volume, 90 breaths/min respiratory rate, 0.8 l/min flow rate; Harvard Apparatus, Holliston, MA). The ventilator exhaust was ported to a hood to avoid isoflurane contamination of the room. An external heating pad was used to maintain a core temperature of 37°C. During all procedures, body temperature, ECG, and respiration were monitored using a rodent monitoring system (Echo: Indus Instruments, Houston, TX; MRI: SA Instruments, Stony Brook, NY; Cath: PowerLab, ADInstruments, Colorado Springs, CO).
Echo
After shaving the chest, a depilatory cream (Nair; Carter-Horner, Mississauga, Ontario, Canada) was applied. The ultrasound transmission gel was kept in the Thermasonic gel warmer (Parker Laboratories, Fairfield, NJ for both) at 37°C. Transthoracic 2-D, M-mode, and pulsed-wave Doppler Echo (Vevo 770 ultrasound system; VisualSonics) were obtained with a broadband scan head centered at 25 MHz (12.5-37.5 MHz imaging band, 20 mm lateral field of view, 15 mm focal length, and 70 -140 m axial-lateral resolution). M-mode and 2-D modalities were applied to measure RV free wall (RVFW) thickness during end diastole using right parasternal long-axis view. These images were obtained from the right side of the rat, with the ultrasonic beam positioned perpendicularly to the wall of the midthird of the RV. PA diameter was measured at the level of pulmonary outflow tract during midsystole using the superior angulation of the parasternal short-axis view (Fig. 1A) . M-mode measurements were performed from "leading edge to leading edge" (epicardial to endocardial) as recommended by the American Society of Echocardiography.
Pulsed-wave Doppler was used to measure PA acceleration time (PAAT) and PA flow velocity time integral (VTI). The Doppler sample volume was centrally positioned within the main PA, just distal from the pulmonary valve with the beam oriented parallel to the flow. The sweep speed for the Doppler flow recordings was 400 -800 mm/s (Fig. 1B) . RV ejection time (ET) was measured as the interval from the onset to the end of ejection in milliseconds. Stroke volume (SV), CO, and cardiac index (CI) were calculated using the formula in Fig. 1, A and B.
MRI
MRI was acquired on a 9.4-T BioSpec system (Bruker BioSpin) using a 72-mm inner diameter volume coil. PA flow was measured in cross-sectional image plane located halfway between the valve and the pulmonary bifurcation. A phase-contrast pulse sequence with a velocity encoding parameter (VENC) of 80 -90 cm/s was used. The sequence parameters were echo time (TE) ϭ 2.1 ms, repetition time (TR) ϭ 10 ms, flip angle ϭ 30°, 128 square matrix, in-plane resolution ϭ 297 m, and slice thickness ϭ 1.5 mm. Since phasevelocity images involve two acquisitions for each velocity image, it is very important to minimize motion due to cardiac or respiratory gating. This was done by keeping the vitals of the animals steady and acquiring one line of k-space at the same part of the respiratory cycle. This resulted in an acquisition time of 2-3 min per image. Since the TR could not be lower than ϳ10 ms due to gradient limitations, an interleaved acquisition provided a 5-ms temporal resolution while doubling the scan time. Images were analyzed using custom software written in MATLAB (Natick, MA). In each time frame, the PA was traced and flow was measured by adding the multiple of the velocity for each pixel by the area represented by that pixel. SV was calculated as the integral of the portion of the flow-time curve representing systole ( Fig. 1, C and D) . CO was calculated as SV ϫ heart rate. CI was calculated as CO/body weight in grams.
To assess RV mass, ECG-and respiratory-gated fast gradient echo (FLASH) cine images were acquired using the following parameters: TE ϭ 3 ms, TR ϭ 10 ms, flip angle ϭ 20, field of view ϭ 4.5 cm, 256 ϫ 192 matrix, in-plane resolution ϭ 175 m, slice thickness ϭ 1 mm, and 13-17 frames/heartbeat. A set of 7 short-axis images was acquired to cover the RV. The right and left ventricles were manually or semiautomatically segmented using the image analysis software Segment v1.8 (Medviso, Lund, Sweden) (13) . The volumes for each cavity wall were found by summing the area of each slice contour multiplied by the slice thickness and slice gap. Mass was calculated as density multiplied by volume.
Cath of Closed-Chest Rat
A 1.4-F micromanometer-tipped Millar pressure catheter (Millar Instruments) was used to measure LVEDP, RV pressure, and systolic (sPAP) and mean PA pressure (mPAP) in control and MCT PAH rats. After intubation and shaving, a 2-cm-long vertical incision was made in the middle of the neck. The underlying tissues were carefully Table 1 dissected to expose the right carotid artery and jugular vein. After the proximal part of the carotid artery was ligated, a small incision was made just below the ligature. The catheter was then threaded through the needle into the LV to measure the LVEDP. Subsequently, the pressure catheter was removed, and a thermistor probe catheter (Physitemp Instruments, Clifton, NJ) was advanced into the aorta via the same arteriotomy. A 22-gauge catheter was gently introduced into jugular vein via cut-down technique. A bolus of iced saline (0.3 ml) was injected, and a thermodilution curve (temperature vs. time) was recorded. CO was then determined by calculating the area under the temperature curve (25) . CI was calculated as CO/body weight in grams. Next, the jugular catheter was replaced with a custom-made sheath system. A PE-50 sheath [1.6-mm outer diameter (OD); Warner Instruments] was inserted to the superior vena cava as a guide for PE-50 tube (0.97-mm OD), which was curved, creating an angle of 80°at the distal 1 cm, to resemble a shepherd's crook. Once a PA pressure waveform was obtained, the micromanometer pressure catheter was advanced into the PA. High-fidelity pressures were recorded and analyzed using a PowerLab data acquisition module and LabChart 6.0 software (ADInstruments). PVR was calculated as (mPAP Ϫ LVEDP)/CO.
. Echocardiographic, MRI, invasive hemodynamic, and autopsy characteristics of control and MCT-induced PAH rats
Gross Anatomy Postmortem
Animals were euthanized after hemodynamic measurements by removing the heart under deep anesthesia (isoflurane 4%). The RV weight and RV-to-[LV ϩ interventricular septum (IVS)] ratio were used as measures of RV hypertrophy (RVH).
Statistics
Values were normally distributed. Continuous variables were expressed as means Ϯ SE. Intergroup differences were assessed using an unpaired Student's t-test or one-way analysis of variance followed by post hoc Bonferroni correction for multiple comparisons, as appropriate. Pearson correlation test and linear regression analyses were used to determine the correlation between the hemodynamic and structural measurements obtained using Echo, MRI, and Cath. A P value of Ͻ0.05 was considered statistically significant. Table 1 summarizes the hemodynamic and structural characteristics obtained by Echo, MRI, cardiac Cath, and autopsy in control and MCT rats. MCT caused PAH and RVH (P Ͻ 0.05 vs. control). HR was slower and CO and CI were reduced in MCT vs. control rats (P Ͻ 0.05).
RESULTS
Representative Echo and MRI images and Cath tracings show the evolution of MCT-induced PAH and RVH in three representative rats (control, 3 wk post-MCT, and 4 wk post-MCT; Fig. 2, A-C, and Fig. 3, A and B) . As PAH progresses, the following changes were noted: 1) shortening of PAAT with an accompanying decrease in VTI and SV (similarly imaged by Doppler Echo and MRI; Fig. 2, A and B) ; 2) progressive RVH; 3) flattening of the IVS (Fig. 3B, right) ; and 4) a midsystolic decrease in PA flow velocity or "notch" (Supplemental Fig.  S2A ). The notch is a consistent finding in all rats and is evident starting in the 3rd wk post-MCT. There was strong direct correlation between the duration of the notch vs. PAP, such that the longer the notch duration, the more severe the PH (Supplemental Fig. S2, B and C) . There was also a correlation between notch duration and the degree of RVH RVFW thickness (Supplemental Fig. S2D ). There was no relationship between the velocity of the PA flow systolic notch and pressures or RVFW thickness.
Assessment of Pulmonary Hemodynamics by Echo and MRI vs. Cath
PAAT. PAAT and PAAT/ET measured by Echo had a strong inverse correlation with sPAP and mPAP measured by cardiac Cath (r 2 ϭ 0.78 and 0.68, respectively, P Ͻ 0.001 for PAAT; r 2 ϭ 0.77 and 0.70, respectively, P Ͻ 0.0001 for PAAT/ET; Fig. 4 , A and B, and Supplemental Fig. S4, A and B) . PAAT measured by MRI also had a strong negative correlation with sPAP and mPAP measured by cardiac Cath (r 2 ϭ 0.74 and 0.76, respectively, P Ͻ 0.01 for each; Fig. 4, D and E) . In addition, PAAT measured by Echo and MRI predicted invasive PVR (Fig. 4, C-F) . There was a strong correlation between PAAT measured by Echo and MRI (r 2 ϭ 0.868, P ϭ 0.0003; Supplemental Fig. S4C) .
CO. There were strong positive correlations between CO and CI as assessed by Echo and MRI and by Cath (Fig. 5, A and B, and Supplemental Fig. S3, C and D) . There was excellent correlation between the two noninvasive methods for measuring CO and CI (r 2 ϭ 0.86 and 0.88, P Ͻ 0.001 for each) and SV (r 2 ϭ 0.74, P Ͻ 0.01; Fig. 5 , C and D, and Supplemental Fig. S3B ). HR measured during Echo, Cath, and MRI did not differ (Supplemental Fig. S3A ).
Assessment of RVH by Echo and MRI vs. Autopsy
A strong, direct correlation was observed between the RVFW diastolic thickness assessed by M-mode Echo with postmortem RV weight (r 2 ϭ 0.72, P Ͻ 0.0001). RVFW also correlated closely with other conventional measures of RVH, including the postmortem RV-to-(LV ϩ IVS) ratio (r 2 ϭ 0.62, P Ͻ 0.0001; Fig. 6, A and B) . RV mass measured by MRI strongly correlated with postmortem RV weight (r 2 ϭ 0.87, P Ͻ 0.001) and RV-to-(LV ϩ IVS) ratio (Fig. 6, D and E) . The two noninvasive techniques yielded highly concordant estimates of RVH: r 2 ϭ 0.83, P Ͻ 0.001 (Fig. 6C ). There was strong direct correlation between RVFW thickness and the severity of PH (Fig. 7, A-C) and between PAAT assessed by Echo and RVFW: r 2 ϭ 0.87, P Ͻ 0.0001 (Fig. 6D) . Also, correlation was noted between postmortem RV and RV-to-(LV ϩ IVS) ratio (Fig. 6F) .
Serial Assessment of Pulmonary Hemodynamics in PAH
The first parameter to change following MCT was PAAT, which decreased significantly by week 3, and this was associated with a decrease in PA flow velocity and appearance of systolic notching (Fig. 8A) . A significant reduction of PAAT/ET was observed only at week 4 (Fig. 8B) . All Cath pressure (sPAP, mPAP, and RVSP) values significantly increased only at week 4 (Fig. 8, D-F) . HR was significantly higher during Echo vs. Cath at week 1 post-MCT, but this did not persist in weeks 2-4 [361 Ϯ 27 and 296 Ϯ 11 beats/min (bpm), respectively, P Ͻ 0.05, for week 1; 333 Ϯ 18 and 315 Ϯ 17 bpm, respectively, P ϭ not significant, for weeks [2] [3] [4] . Like changes in PAP, RVH developed later than changes in Doppler, being significant only at week 4 (Fig. 8, C, G, and H) .
DISCUSSION
In this study, we demonstrated in normal rats and rats with MCT-induced PAH an excellent correlation in the quantitation of important pulmonary vascular hemodynamics characteristics (PAP, CO, and PVR) and RVH, as assessed by two newer noninvasive methods, high-frequency Echo and high-fieldstrength MRI. Importantly, we validated these noninvasive measures against a very high standard, high-fidelity Cath using micromanometer-tipped catheters conducted in closed-chest, lightly anesthetized rats. As in humans, Cath remains the gold standard for the measurements of pressure and flow in the pulmonary circulation. However, these data suggest that either of these new high-resolution, noninvasive techniques can accurately estimate mPAP, CO, and PVR. Additionally, we developed protocols for use of low-dose, inhaled isoflurane anesthesia, which allowed imaging without hemodynamic compromise (as evidenced by preservation of a physiological heart rate). Several features of the experimental design strengthen the study, including the use of imaging scientists blinded to each other's findings and the fact that the different imaging modalities were conducted within close temporal proximity (Ͻ2 days), which minimized the confounding effects of change in disease state. To our knowledge, this is the first study to measure blood flow in the PA of rodents using MRI.
Doppler Echo assessment of pulmonary hemodynamics in humans often relies on continuous wave (CW) Doppler interrogation of tricuspid regurgitation and subsequent calculation of PAP using the modified Bernoulli equation (41) . Even in humans, this technique is often inaccurate, both under-and overestimating PAP (4, 37) . Moreover, in rodent models of PAH, tricuspid regurgitation is rarely sufficient to detect and quantify, particularly as many machines lack color and CW Doppler.
Alternatively, PA pressure can be estimated by measurement of PAAT. PAAT can be measured in humans and has good diagnostic accuracy as a measure of PAP (5, 12, 18) . PAAT correlates well with both sPAP and mPAP in patients with congenital heart disease (21). However, PAAT has not become as widely used as the tricuspid regurgitation method, both due to the simplicity of the latter and because of some technical challenges required to accurately record the PA flow velocity signal. To accurately measure the relatively short time between onset of flow and peak flow (the acceleration time), high sweep speed recordings of PA Doppler are required. If Doppler acquisition is not optimized (fast sweep speed and optimal gain and scale), small errors in measuring the PAAT can lead to large errors in calculated PAP. Another challenge is the fact that the relationship between PAAT and PAP is not a simple fluid hydraulics relationship; rather, each laboratory must derive its own regression equation. Nonetheless, the PAAT has a unique advantage in reflecting the biophysical properties of the downstream pulmonary vascular bed. A remodeled, noncompliant vascular bed causes a reflection wave to rapidly return toward the pulmonic valve in midsystole, causing early cessation or transient diminution of forward velocity (the observed notching of the PA Doppler signal; Supplemental Fig. S2A ) (36) . The timing of the notch is inversely related to pressure and correlates well with elevated sPAP and PVR (36) . Our results also showed excellent correlation between the mPAP and sPAP vs. PA flow (Doppler) notch duration (Supplemental Fig. S2, B and C) . There was also a correlation between notch duration and the degree of RVH (Supplemental Fig. S2D) .
Remarkably, every rat exposed to MCT developed significant shortening of PAAT, and the more severe the PAH, the shorter the PAAT. Regression analysis showed it to be a highly predictive measure of sPAP and mPAP (Fig. 4, A and B) and moderately predictive of PVR (Fig. 4C) . Similarly accurate measure of mPAP can be obtained whether the PAAT is derived from Doppler or MRI (Fig. 4, D-F) . Calculation of mPAP from the PAAT can be accomplished using the regression formula mPAP ϭ 58.7 Ϫ (1.21 ϫ PAAT). The reproducibility and ease of acquisition make PAAT an ideal measure of PAH in rats. Our findings are consistent with those of Jones et al. (15) , who described changes in the PA waveform and PAAT beginning at week 3 post-MCT. PAAT shortened as the sPAP, measured by right heart Cath, reached 25-30 mmHg. They reported a linear correlation between the PAAT and sPAP over a wide range of pressures from 30 to 65 mmHg. It is noteworthy that tricuspid regurgitation developed only late in this model (week 6 or at sPAP Ͼ 65 mmHg), which speaks to the superiority of PAAT in quantification of experimental PAH. They concluded that PAAT offered a noninvasive estimate of the sPAP over a wide range of pressures. There are several differences between our study and that of Jones et al. (15) . Whereas ketamine and xylazine were used in their study, we used inhaled isoflurane, which likely reflects the more physiological heart rates noted in our study (333 Ϯ 17 bpm) vs. theirs (267 Ϯ 20 bpm). The ultrasound platforms used also differed between the studies. Jones et al. (15) used a conventional machine, with a 15-MHz transducer and a sweep speed for the Doppler PA flow of Յ200 mm/s, whereas we used a high-resolution ultrasound system with a 37.5-MHz transducer and a sweep speed of 400 -800 mm/s, which allows more precise measurement of PAAT. Nonetheless, our paper supports their conclusions and extends them by showing similar findings can be obtained using the 9.4-T MRI.
Tachycardia can reduce the accuracy of PAAT as a predictor of mPAP. Augmentation in heart rate shortens PAAT in swine at lower mPAP; however, high heart rates have little additional effect on PAAT at higher mPAP (24) . Heart rate variability was not a factor in our study, a testimony to the benefits of low-dose, inhaled isoflurane anesthesia. The average dose of isoflurane used was 1.8 Ϯ 0.1% for both noninvasive techniques, and duration was shorter (24 Ϯ 1 min) for Echo compared with 60 min for MRI. Our study also showed an excellent inverse correlation between Doppler PAAT and MRI PAAT with PAP measure by right heart Cath (Fig. 4, B and E) , as previously reported by Dabestani et al. (5) . They also noted that Doppler PAAT decreased as total pulmonary vascular resistance increased (r 2 ϭ Ϫ0.86). They found a normal PAAT of 134 Ϯ 20 ms in humans and a PAAT of 88 Ϯ 25 ms in those with mPAP Ͼ20 mmHg (5); in rats, PAAT duration is ϳ4 times shorter (33.4 Ϯ 1.1 vs. 22.1 Ϯ 1.4, in control vs. PAH; Table 1 ). We have been able to use PAAT to detect hypoxic pulmonary vasoconstriction in vivo (30) and to assess regression of experimental PAH (26). Echo correlates with Cath hemodynamics and has the advantage of being noninvasive. However, Echo cannot accurately measure LVEDP, although it is useful to exclude many causes of pulmonary venous hypertension (such as LV systolic or diastolic dysfunction, LV hypertrophy, valvular heart disease, or shunting). Nonetheless, we show that PVR, as calculated in closed-chest rats using high-fidelity catheters, correlates well with PAAT (Fig. 4, C and F) . These findings are consistent with those of Koskenvuo et al. (20) . They used Echo Doppler to estimate PAP and PVR in rats with MCT-induced PAH and showed a good correlation with invasive hemodynamic measurements (20) . The main differences from our study were the frequency of the transducer (their 15 vs. our 37.5 MHz) and the fact that they did not use MRI.
There are a number of potential risks associated with the gold standard, cardiac Cath, which in many ways are amplified in rodents because of their small size. Complications include damage of the jugular vein, thrombosis, bleeding, arrhythmias, and cardiac arrest, both in humans and experimental animals (29, 34) . These complications are particularly important if serial studies are being performed. Here, we describe the technique for closed-chest Cath that minimizes artifacts and volume shifts related to thoracotomy techniques of direct catheter insertion and avoids damping artifacts related to the use of fluid-filled catheters. The hemodynamic traces obtained with this system equal or exceed the quality of recordings obtained in the human Cath laboratory. Moreover, we show that the thermodilution technique of measuring CO can readily and reliably be performed and yields similar results as obtained by Echo Doppler or MRI (Supplemental Fig. S3, C and D) .
Imaging methods for small animals have been adopted from human systems and have marginal spatial and temporal resolutions (high frame rates) when used in rodents (11) . A wide variety of physiological data and accurate anatomy can be obtained using ultrasound systems that have been specifically designed for use on small animals (6). With newly developed instrumentation such as the VisualSonics Vevo 770, one can obtain in vivo images at levels of resolution approaching 30 m (i.e., anatomic resolution). Indeed, both Echo and MRI were as good as autopsy in measuring RV wall thickness and mass (Fig. 6, A, B, D and E) .
Using high-frequency ultrasound, we could easily document changes of PAH and RVH on a weekly basis by Echo and confirm the accuracy of this assessment by Cath and autopsy data. There was no significant change in the pulmonary hemodynamics and RVH up to 2 wk after injection of MCT. The first parameter to change was PAAT at week 3 after MCT, accompanied by changes in the morphology of the PA flow (systolic notching). In our data, significant shortening of the duration of PAAT (Echo) developed as PAH evolved post-MCT at week 3, although PA pressures (Cath) dramatically increased at week 4, as did RVH (Fig. 8, A-H) . In a study of Blood-flow measurements by MRI are especially difficult in the great vessels due to respiratory and cardiac motion and high heart rates of rodents. Previously, phase-contrast cardiac MRI has been used on rats to measure flow in the coronaries of the isolated heart (19) or in the cardiac cavities (40) . MRI procedures for blood-flow assessment have evolved very recently. In mice, blood flow has been measured in the ascending aorta using very high-field-strength MRI (17.6 T) (14) . Our data showed very good inverse relationship between MRI PAAT with invasive PAP and PVR (Fig. 4, D-F) . Also, PAAT correlated very well between both noninvasive methods (Supplemental Fig. S4D ).
Thermodilution has been successfully used to measure CO in rats (17, 31) . The technique is based on detection of changes in aortic temperature by a thoracic aortic thermistor in response to venous injections of saline (Fig. 2C, right) . Kissling et al. (17) measured CO with thermal dilution and simultaneously with Fick method and/or with electromagnetic flowmetry. Although all three techniques correlated well, and the Fick method and electromagnetic flow techniques yielded identical results, the thermodilution technique yielded higher CO values under conditions of low CO (17) . Our study demonstrates excellent correlations in CO as determined by noninvasive techniques and thermodilution over the wide range of values seen in normal and pulmonary hypertensive rodents (Supplemental Fig. S3, B-D, and Fig. 5, A, B, and D) .
Likewise, we demonstrate that both Echo and MRI accurately measure the mass and thickness of the RV, using autopsy as the gold standard. Our data demonstrate excellent correlation between the diastolic thickness of RVFW, determined by M-mode Echo and RV mass, as assessed using MRI (Fig. 6C) . Postmortem data showed that the RV weight correlated very well with Echo measures of RVFW (Fig. 6, A and B) . Likewise, RV weight at autopsy correlated well with RV mass measured by MRI (Fig. 6, D and E) . Similar results have been obtained in humans, where MRI is accepted as the gold standard for RV volumetry, wall thickness, and mass evaluation in humans with PAH (38) . Because MRI techniques do not depend on geometric assumptions about the complex shape of the RV, they may be used for accurate and reproducible quantitation of RV volume and myocardial mass. Although findings with high-resolution Echo and MRI were comparable in our study, the equipment to perform high-resolution Echo is substantially less expensive, and it is less time consuming than rodent MRI. Thus, although both are useful tools, the highresolution Echo may for practical reasons be more widely useful in studies of the right heart and pulmonary circulation of rodents.
Because some investigators have found it difficult to advance the relatively rigid and fragile Millar catheter into the PA, we assessed the relationship between the invasive RVSP and the mPAP (important because mPAP is used to calculate PVR). As expected, there is an extremely close correlation between these hemodynamic variables, and mPAP can be predicted from RVSP using the regression formula mPAP ϭ RVSP ϫ 0.65 ϩ 0.55 mmHg (Supplemental Fig. S5 ; r 2 ϭ 0.81, P Ͻ 0.0001).
Limitations
There were several limitations in the study. We were unable to estimate sPAP using Bernoulli equation and the tricuspid regurgitation jet velocity because the mechanical transducer of the VEVO 770 lacks the requisite CW Doppler modality and color Doppler. Although one of the strengths of our study was the blinding of each operator to the findings of the others, we could not perform interobserver variability test, because each method was conducted and results were interpreted by only one person. Finally, although we observed progression of PAH, we did not evaluate regression (i.e., did not test the effects of experimental therapies); however, we have done so in the past (2).
Conclusions
Our work shows an excellent correlation between two stateof-the-art noninvasive techniques, high-frequency Echo and high-field-strength MRI, and demonstrates that both correlate well with high-fidelity Cath and postmortem data. This study justifies the use of both techniques in assessing the pulmonary hemodynamics and RV in normal animals and in rat models of PAH. Significant progression of PAH and RVH are evident only 3-4 wk after injection of MCT. The creation of core facilities, staffed by expert sonographers and biomedical engineers, could improve the quality and translational relevance of rodent research in the field of PH.
